Benefits
Metabolic Rate: Small and Not Significant for Synephrine Alone
The figure usually quoted, a 65 kcal rise in resting metabolic rate, comes from one small industry-funded study with 10 people per group, measured once 75 minutes after a 50 mg dose, and that 65 kcal difference was not statistically significant. Only the arm combining 50 mg p-synephrine with 600 mg naringin and 100 mg hesperidin reached significance. A separate trial that added 20 mg of p-synephrine to a caffeinated pre-workout found no additive benefit from the synephrine.
Weight Loss: Measured and Not Found
This is what the ingredient is sold for, and it has been tested. A 2022 meta-analysis pooling 18 placebo-controlled human trials found no significant weight loss in the synephrine groups after prolonged treatment and no change in body-composition measures. An earlier systematic review found only one eligible randomized placebo-controlled trial, in 20 people over 6 weeks, which also showed no significant weight loss.
Exercise Performance: Tested and Null
Performance has been measured directly and synephrine did not improve it. In 13 experienced sprinters, 3 mg/kg changed nothing on jump height, 60 m speed or 100 m speed. In 80 resistance-trained men taking a pre-workout for 8 weeks, adding 20 mg of synephrine produced no extra gain in strength, anaerobic capacity or body composition over the same pre-workout without it.
Fat Oxidation During Exercise: A Fuel-Mix Shift, Not Fat Loss
In randomized crossover trials, single doses of 1 to 3 mg/kg raised the maximum rate of whole-body fat oxidation during cycling, without changing total energy expenditure. Those doses are roughly 70 to 210 mg, well above the 10 to 50 mg found in most products. This is a change in which fuel the body burns during one exercise test, measured by breath gas analysis, and it has not translated into measured fat loss in the placebo-controlled trials. Every one of these trials comes from the same laboratory and none has been independently replicated.
Mechanism of action
Adrenergic Activity: Beta-3 Selectivity Not Shown in Humans
p-Synephrine is a low-potency sympathomimetic that acts at several adrenergic receptors. The beta-3 selectivity often claimed for it comes from rodent fat-cell work; in isolated human fat cells synephrine does not stimulate lipolysis at achievable concentrations. Its measured effects in people, mainly a rise in blood pressure with prolonged use, fit general weak adrenergic activity rather than selective beta-3 agonism.
Limited CNS Penetration
Unlike ephedrine, p-synephrine carries a polar para-hydroxyl group that limits its blood-brain-barrier penetration. This is the pharmacological basis for its relatively muted CNS stimulant profile at typical supplemental doses.
Blood Pressure: Rises With Prolonged Use
Single-dose studies are mixed: some found no change in heart rate or blood pressure, while a randomized placebo-controlled crossover trial in 15 healthy adults given 900 mg bitter orange extract standardized to 6 percent synephrine found systolic pressure up to 7.3 mmHg higher than placebo for 5 hours, diastolic up to 2.6 mmHg higher, and heart rate up to 4.2 beats per minute higher. Pooling 18 placebo-controlled trials, systolic pressure rose 6.4 mmHg and diastolic 4.3 mmHg with prolonged use. Combination with high-dose caffeine adds to the effect.
Clinical trials
A narrative review, not a trial. It summarizes over 20 published and unpublished human studies totalling about 360 subjects. All three authors disclose having served as paid consultants to Nutratech, Inc., a company that markets bitter orange extract, and the company supplied some of the unpublished reports.
About 360 subjects pooled across more than 20 separate studies. Roughly 44 percent took a p-synephrine-only product; the rest took multi-ingredient products, and about two thirds of the overweight or obese participants also took 132 to 528 mg/day of caffeine.
The review reports that p-synephrine did not significantly raise heart rate or blood pressure, increased resting metabolic rate and energy expenditure, and produced modest weight loss when given for 6 to 12 weeks, mostly in products that also contained caffeine. A later independent meta-analysis of 18 placebo-controlled trials reached the opposite conclusion on both counts: no significant weight loss, and blood pressure rising with prolonged use.
A safety review, not a trial. It gathers published case reports and adverse-event filings involving bitter-orange-containing weight-management products, alongside animal, in vitro and receptor-binding data. All three authors have disclosed, in a companion review of the same literature, that they served as paid consultants to a company that markets bitter orange extract.
No study population: this is a review of case reports and adverse-event filings, not a study in volunteers.
Almost every case report involved a multi-ingredient product containing caffeine or other stimulants, and none measured how much p-synephrine the product actually contained, so no single case isolates synephrine as the cause. The authors conclude on that basis that bitter orange and p-synephrine appear safe at typical doses. Independent risk assessors read the same case series differently: the reported events are cardiovascular (hypertension, arrhythmia, myocardial infarction), they cluster in synephrine plus caffeine products used around exercise, and Germany's BfR and France's ANSES both issued restrictive advice on that basis.
Earlier review evaluating Citrus aurantium and synephrine alkaloids for overweight and obesity, covering animal studies, human weight-loss trials, physiological assessments and case reports through 2005.
No study population: this is a review, and its inputs include animal studies and case reports as well as small human trials.
The reviewers concluded that while preliminary data were promising, larger and more rigorous clinical trials were needed to draw firm conclusions on safety and efficacy of bitter orange and synephrine alkaloids for weight loss. This review formed part of the historical safety conversation around the ingredient.